# CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

> **NCT03904251** · PHASE1 · TERMINATED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 13 (actual)

## Conditions studied

- Acute Myelogenous Leukemia

## Interventions

- **DRUG:** Gemtuzumab Ozogamicin
- **DRUG:** Liposome-encapsulated Daunorubicin-Cytarabine

## Key facts

- **NCT ID:** NCT03904251
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-18
- **Primary completion:** 2023-10-25
- **Final completion:** 2023-10-25
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2023-11-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03904251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03904251, "CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03904251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*